Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi; Lorenzo F. Fanchi; Krijn K. Dijkstra; José G. van den Berg; Arend G. J. Aalbers; Karolina Sikorska; Marta López‐Yurda; Cecile Grootscholten; Geerard L. Beets; Pétur Snæbjörnsson; Monique Maas; Marjolijn Mertz; Vivien Veninga; Gergana Bounova; Annegien Broeks; Regina G. H. Beets‐Tan; Thomas R. de Wijkerslooth; Anja U. van Lent; Hendrik A. Marsman; Elvira Nuijten; Niels F.M. Kok; Maria Kuiper; Wieke H.M. Verbeek; Marleen Kok; Monique E. van Leerdam; Ton N. Schumacher; Emile E. Voest; John B.A.G. Haanen

doi:10.1038/s41591-020-0805-8

Keywords

NivolumabMedicineIpilimumabOncologyTremelimumabInternal medicineColorectal cancerImmunotherapyCancer

Affiliated Institutions

Related Publications

Immunotherapy in colorectal cancer: rationale, challenges and potential

Karuna Ganesh , Zsofia K. Stadler , Andrea Cercek +4 more

Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a su...

2019 Nature Reviews Gastroenterology & Hep... 1861 citations

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le , Jennifer N. Durham , Kellie N. Smith +43 more

Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy....

2017 Science 6334 citations

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

Miriam Koopman , Guus A. M. Kortman , Leonie J. Mekenkamp +5 more

A deficient mismatch repair system (dMMR) is present in 10-20% of patients with sporadic colorectal cancer (CRC) and is associated with a favourable prognosis in early stage dis...

2009 British Journal of Cancer 501 citations

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

Daniel Wang , Joe‐Elie Salem , Justine V. Cohen +24 more

In the largest evaluation of fatal ICI-associated toxic effects published to date to our knowledge, we observed early onset of death with varied causes and frequencies depending...

2018 JAMA Oncology 2385 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Mario Sznol , John D. Powderly , David C. Smith +7 more

2506 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a fully human IgG4 PD-1 blocking antibody, has shown antitum...

2010 Journal of Clinical Oncology 84 citations

Publication Info

Year: 2020
Type: article
Volume: 26
Issue: 4
Pages: 566-576
Citations: 1282
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1282

OpenAlex

Cite This

APA Style

                            
                                
                                    Myriam Chalabi, 
                                
                                    Lorenzo F. Fanchi, 
                                
                                    Krijn K. Dijkstra
                                
                                et al.
                            
                            (2020). 
                            Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. 
                            Nature Medicine
                            , 26
                            (4)
                            , 566-576.
                            https://doi.org/10.1038/s41591-020-0805-8
                        

Identifiers

DOI: 10.1038/s41591-020-0805-8